Oscar Health (NYSE:OSCR) Insider Janet Liang Sells 12,475 Shares of Stock

Oscar Health, Inc. (NYSE:OSCR) insider Janet Liang sold 12,475 shares of Oscar Health stock in a transaction dated Tuesday, June 2nd. The stock was sold at an average price of $21.94, for a total value of $273,701.50. Following the completion of the transaction, the insider owned 259,057 shares of the company’s stock, valued at $5,683,710.58. This trade represents a 4.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Oscar Health Stock Performance

Shares of OSCR stock opened at $23.54 on Friday. The company has a quick ratio of 1.11, a current ratio of 1.11 and a debt-to-equity ratio of 0.26. The business has a 50 day moving average of $18.15 and a two-hundred day moving average of $16.00. Oscar Health, Inc. has a 52 week low of $10.69 and a 52 week high of $25.58. The company has a market cap of $7.10 billion, a P/E ratio of -39.90, a PEG ratio of 1.43 and a beta of 2.37.

Oscar Health (NYSE:OSCR) last issued its earnings results on Wednesday, May 6th. The company reported $2.07 EPS for the quarter, beating analysts’ consensus estimates of $1.11 by $0.96. Oscar Health had a negative return on equity of 3.26% and a negative net margin of 0.30%.The company had revenue of $4.65 billion during the quarter, compared to the consensus estimate of $4.90 billion. During the same period in the previous year, the firm posted $0.92 earnings per share. Oscar Health’s quarterly revenue was up 52.6% compared to the same quarter last year. As a group, analysts anticipate that Oscar Health, Inc. will post 0.47 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on OSCR shares. Jefferies Financial Group upgraded Oscar Health from an “underperform” rating to a “hold” rating and lifted their target price for the company from $10.00 to $16.00 in a research note on Monday, April 20th. Robert W. Baird lifted their target price on Oscar Health from $15.00 to $19.00 and gave the company a “neutral” rating in a research note on Thursday, May 7th. Wells Fargo & Company set a $20.00 target price on Oscar Health and gave the company an “equal weight” rating in a research note on Thursday. Wolfe Research assumed coverage on shares of Oscar Health in a research report on Tuesday, May 5th. They issued a “peer perform” rating for the company. Finally, UBS Group upped their target price on shares of Oscar Health from $15.00 to $20.00 and gave the stock a “neutral” rating in a research report on Thursday, May 7th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $20.22.

Key Stories Impacting Oscar Health

Here are the key news stories impacting Oscar Health this week:

• Positive Sentiment: Wells Fargo upgraded Oscar Health from “strong sell” to “hold”, suggesting the worst of the downside may be behind the stock even though the new $20 target still sits below the current share price. Zacks.com
• Positive Sentiment: A news item that Oscar Health co-founder is shifting into an advisory leadership role appears to be an internal transition rather than a disruptive change, which may be viewed as manageable by investors. Oscar Health Co-Founder Shifts to Advisory Leadership Role
• Neutral Sentiment: Oscar Health reported strong first-quarter EPS of $2.07, beating estimates by a wide margin, though revenue came in below expectations. The earnings beat supports the company’s fundamentals, but the softer revenue print limits the upside reaction.
• Neutral Sentiment: Multiple insiders, including CFO Richard Scott Blackley, Janet Liang, Adam Mcananey, Director Mario Schlosser, and CAO Victoria Baltrus, sold shares under pre-arranged 10b5-1 plans to cover tax withholding on vested equity awards. Because these were scheduled transactions, they are less alarming than discretionary selling, but the cluster of sales can still pressure sentiment.
• Negative Sentiment: The most notable insider sale was by Director Mario Schlosser, who sold 34,120 shares, adding to the perception that leadership is reducing exposure even if the trade was pre-planned.

Hedge Funds Weigh In On Oscar Health

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Quarry LP grew its holdings in Oscar Health by 439.8% in the 3rd quarter. Quarry LP now owns 1,803 shares of the company’s stock worth $34,000 after buying an additional 1,469 shares in the last quarter. Tsfg LLC bought a new position in Oscar Health in the 3rd quarter worth approximately $38,000. Jones Financial Companies Lllp raised its holdings in Oscar Health by 7,473.3% during the first quarter. Jones Financial Companies Lllp now owns 2,272 shares of the company’s stock worth $30,000 after purchasing an additional 2,242 shares in the last quarter. Strs Ohio acquired a new stake in Oscar Health in the first quarter worth approximately $30,000. Finally, Fifth Third Bancorp lifted its position in Oscar Health by 148.7% in the fourth quarter. Fifth Third Bancorp now owns 2,363 shares of the company’s stock worth $34,000 after purchasing an additional 1,413 shares during the period. 75.70% of the stock is owned by institutional investors.

About Oscar Health

Oscar Health, trading on the New York Stock Exchange under the ticker OSCR, is a technology-driven health insurance company headquartered in New York, New York. Founded in 2012 by Mario Schlosser, Joshua Kushner and Kevin Nazemi, the company was built with the goal of simplifying healthcare coverage and enhancing member experience. Oscar leverages a proprietary digital platform to streamline plan enrollment, claims administration and member support, distinguishing itself in the individual, family and small group insurance markets.

The company’s primary products include on-exchange individual and family medical plans under the Affordable Care Act, off-exchange plans, as well as Medicare Advantage offerings.